mirikizumab
NICE recommends mirikizumab (Omvoh â–¼) for previously treated moderately to severely active Crohn’s disease 1
May 30, 2025Research and Development Crohn’s disease, Eli Lilly and Company, Gastrointestinal tract, Medicines and Healthcare products Regulatory Agency (MHRA)(, NHS England and Wales, National Institute for Health and Care Excellence (NICE), Omvoh, inflammatory bowel disease (IBD), mirikizumab
In the Phase 3 VIVID-1 trial, patients treated with mirikizumab experienced significant improvement in clinical remission and endoscopic response at …
Eli Lilly shares positive results from phase 3 VIVID-1 trial of Crohn’s disease treatment
May 22, 2024Medical Communications Crohn’s disease, Eli Lilly, Endocrinology, clinical trial, mirikizumab
Eli Lilly has announced results from its pivotal phase 3 VIVID-1 study, which assessed patients with moderately to severely active …
Amsterdam UMC’s new drug doubles remission rates in patients with ulcerative colitis
July 4, 2023Research and Development Amsterdam UMC, Gastrointestinal tract, mirikizumab, ulcerative colitis
A new drug, being investigated by Amsterdam UMC along with colleagues at various universities, has been shown to be effective …
Lilly’s ulcerative colitis treatment meets all key endpoints in Phase III trial
March 17, 2021Research and Development Eli Lilly, Phase III trial, lilly, mirikizumab, ulcerative colitis
Eli Lilly’s mirikizumab treatment for ulcerative colitis (UC) patients has met the primary endpoints and all key secondary endpoints in …
